Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Hypertension
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Hypertension
    Updated Boxed Warning for Micro-Bubble Contrast Agents - (DGNews)
    TopAbstracts in Hypertension 07/16/2008 - (DGNews)
    Young Adults With Prehypertension More Likely to Have Atherosclerosis Later in Life - (DGNews)
    TopAbstracts in Hypertension 07/09/2008 - (DGNews)
    TopAbstracts in Hypertension 07/02/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Hypertension
    • Beyond Glycemic Control: Managing Obesity and Cardiovascular Disease Risk for Patients With Type 2 Diabetes in the Primary Care Setting
    • Improving Outcomes in Hypertension and Congestive Heart Failure: Focus on New Generation ß-Blockers
    • Hypertension 102: Resistant Heart
      Pharmacotherapeutic Treatments for Hypertension Complicated with Proteinuria
      Hypertension in the Elderly

      Webcasts/CME archive

       Recent cases - Hypertension
        Dilation of Renal Artery Stenosis after Administration of Losartan
        Angioedema of the Tongue
        Primary Aldosteronism Caused by a Unilateral Adrenal Adenoma Accompanied by Autonomous Cortisol Secretion
        A Case of Hyperreninemic Hypertension with Bilateral Positive Captopril Renography but without Renovascular Stenosis
        Unusual Sequel of Successful Laparoscopic Unilateral Adrenalectomy in a Hypertensive Adolescent

        Cases archive
          




        my personal edition > hypertension > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Low-Dose Eplerenone (EPL) Reduces Proteinuria in Type 2 Diabetes Patients Without Increasing Serum Potassium: Presented at ASH(HYP)

        By Jill Stein

        NEW YORK, NY -- May 15, 2003 -- Eplerenone (EPL) (50 - 100 mg) coadministered with the ACE inhibitor enalapril (ENAL) produces a similar antiproteinuric effect as EPL at a dose of 200 mg, while obviating the elevated potassium levels seen with the higher dose, researchers report.

        The finding was presented here on May 15th at the 18th Annual Scientific Meeting of the American Society of Hypertension.

        EPL, a selective aldosterone blocker recently approved for the treatment of hypertension, was previously shown to decrease proteinuria, but also to increase potassium levels at a dose of 200 mg per day. Murray Epstein, MD of the University of Miami, Miami, Florida, led a team of researchers in determining whether lower doses of EPL would be as effective while reducing this dangerous side effect.

        The multicenter study included 268 patients with type 2 diabetes and albuminuria (with or without a history of hypertension) being treated with ENAL 20 mg.

        Patients were randomized to receive EPL 50 mg or 100 mg daily, or placebo in addition to ENAL therapy. If blood pressure was not controlled at week 4, amlodipine 2.5 mg was added, with the dose doubled every 2 weeks, up to 10 mg, if necessary.

        Uncontrolled hypertension was defined as levels greater than 130/180 mm Hg. Patients were assessed at weeks 4, 8, and 12.

        Patients who received EPL and ENAL in combination had a significantly reduced urinary albumin:creatinine ratio compared with the ENAL monotherapy group.

        Incidence of both sustained and severe potassium increases were similar in the 3 treatment groups, and were not clinically relevant. The incidence rates were generally lower in patients receiving 50 mg or 100 mg EPL coadministered with ENAL when compared with results from an earlier trial that used EPL 200 mg with or without ENAL 10 mg in hypertensive patients with diabetes and albuminuria (Epstein M, et al. Am J Hypertens 2002;15(Suppl 1):A24).

        Other adverse events (including gynecomastia, mastodynia, and impotence) were rare or absent and did not differ among treatment groups.

        This study was sponsored by Pharmacia Corporation of Peapack, New Jersey.


        [Study title: Characterization of the Antiproteinuric Effect of Eplerenone in Patients With Type 2 Diabetes Mellitus. Abstract P-181a]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send